---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279355263.md"
description: "Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suit"
datetime: "2026-03-17T02:28:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279355263.md)
  - [en](https://longbridge.com/en/news/279355263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279355263.md)
---

# 

Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suit

### Related Stocks

- [688336.CN](https://longbridge.com/en/quote/688336.CN.md)
- [688513.CN](https://longbridge.com/en/quote/688513.CN.md)
- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688759.CN](https://longbridge.com/en/quote/688759.CN.md)
- [688382.CN](https://longbridge.com/en/quote/688382.CN.md)
- [603387.CN](https://longbridge.com/en/quote/603387.CN.md)
- [688658.CN](https://longbridge.com/en/quote/688658.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)

## Related News & Research

- [Junshi Biosciences Shareholders Approve H-Share Buyback Mandate](https://longbridge.com/en/news/293923779.md)
- [Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance](https://longbridge.com/en/news/293479960.md)
- [Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer](https://longbridge.com/en/news/293373812.md)
- [Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLC](https://longbridge.com/en/news/293348759.md)
- [Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)](https://longbridge.com/en/news/291476385.md)